Matt Chambless
Analyst · Jeff Garro with William Blair & Company. Please go ahead
Thanks, Boyd, and good afternoon everyone. As we mentioned in the earnings release, the fourth quarter's 12 new Thrive implementations marked our highest point, since 2010, and drove solid results on both the top and bottom lines. Quarterly revenues of $72.3 million are up 4% sequentially, and were the second highest in the history of CPSI, trailing only the fourth quarter of 2017's Meaningful Use-driven results. Non-GAAP EPS effectively matched last quarter's all-time high, and outpaced the fourth quarter of 2017 by 24%. Adjusted EBITDA grew 28% sequentially and reached the highest point since our acquisition of Healthland. We're proud to close out 2018 with such a strong quarter with post-acquisition highs in operating, pre-tax, net, and adjusted EBITDA margins with second-best results for non-GAAP net margin. Operating cash flows for the quarter increased for the third consecutive period to $9.1 million, up nearly 30% sequentially, and over 70% from the fourth quarter of 2017. The combined strengths of our sizable recurring revenue base and cash conversion on existing financing receivables propelled us to our best cash flow period since the first quarter of 2017, all while faced with a $3.5 million further expansion and financing receivables, driven by the record new Thrive implementations. All told, operating cash flows doubled from $7.8 million during the first half of 2018 to $16.1 million during the second half of the year. These strong operating cash flows, particularly in the second-half of the year, allowed for a year-over-year increase in balance sheet cash of $5.2 million, while net payments against long-term debt totaled $11.7 million, including a $5 million advance payment against our revolving credit facility during the fourth quarter. Reduced debt levels, combined with continued EBIDTA execution resulted in our leverage ratio as calculated under the terms of our credit agreement, decreasing from 2.7 to 2.54, just shy of our target of 2.5. Timing issues aside, we expect this elevated level of cash flows to continue into 2019, with financing receivables no longer expected to be a drag on cash flow for the next 12 months. Recurring revenues made up 79% of revenues for the period, and 81% of trailing 12-month revenues. Quarterly revenues grew 2% sequentially and 3% year-over-year with the full fiscal year showing 5% growth in recurring revenues. Moving away from the income statement for a moment, total bookings showed impressive growth as well, increasing 25% sequentially and 19% over the fourth quarter of 2017. TruBridge bookings continued their upward trajectory for the year posting a third consecutive quarter of growth with bookings that were up 6% sequentially and 41% over the fourth quarter of 2017. The software side of our business experienced solid bookings performance as well with increases in nearly all categories driving a 37% sequential increase, while a $3.1 million MU3 booking headwind dragged the year-over-year quarterly increase down to 11%. Of the $15.9 million in system sales and support bookings, roughly $2.2 million is included in our fourth quarter revenues. $9.4 million represents non-subscription sales that should trickle into revenue over the next 12 months, with an average lag between booking and install of five to six months. $4.2 million represents EHR subscription revenue to be recorded over a weighted average period of five years, with a start date in the next 12 months, and similar to our non-subscription sales and average lag between booking and install of five to six months. Our $7.8 million of bookings from TruBridge are nearly all comprised of recurring revenues to be recorded over a one-year period, starting in the next four to six months. Twelve customer sites went live with our Thrive acute care product, compared to six in the previous quarter, and seven in the fourth quarter of 2017. One of this period's go-lives were under a cloud or subscription model compared to none in either the third quarter of 2018 or the fourth quarter of 2017. At this time, we expect six new client facilities to go live with our Thrive solution in the first quarter of 2019 with one expected to go live in a cloud environment. Our employee headcount as of December 31 was roughly 2,020, a 1% decrease from the September 30 number. Turning to the income statement, TruBridge posted results that were relatively flat sequentially, with revenues up 9% year-over-year for the fourth quarter versus the fourth quarter of 2017 with total fiscal year revenues eclipsing prior-year amounts by 13%. Specific to the quarterly numbers, accounts receivable management and insurance services revenues were the primary drivers of the year-over-year quality growth. Accounts receivable management revenues increased 21% year-over-year as hospital clients continued to partner with us for their full business office needs and insurance services revenues increased 10% as consistently strong bookings for the TruBridge RCM solution are beginning to hit full revenue run rate. Increased labor costs contributed to a sequential decline in margins from 45% to 43% while year-over-year quarterly margins improved from 42% to 43%. System sales and support revenues increased $2.8 million sequentially as the eight-year record number of installations resulted in a $3.2 million increase in net new revenues. Year-over-year, quarterly revenues were down $7.8 million as the $2.7 million increase in net new installation revenues was eclipsed by a $9.2 million decline in MU3 related revenues. It's worth noting that the fourth quarter of 2017 was a particularly strong period of MU3 related revenue with $12.3 million of revenue for the related applications compared to $3.1 million in the fourth quarter of 2018. That $12.3 million of a MU3 revenue in the fourth quarter of 2017 makes up roughly 43% of total life-to-date MU3 revenue and is nearly 3x the second highest quarter for such revenues underscoring exactly how outsized an impact this nonrecurring element had on year-over-year comparatives. To date, we've recognized $28.2 million in MU3 related revenue with life-to-date bookings of $30.1 million. Of the remaining $1.9 million of MU3 bookings and backlog, we currently have $1.4 million scheduled for implementation and revenue recognition during the first quarter of 2019. Our cost of system sales and support were down nearly 6% sequentially as hardware costs declined due to revenue mix. Costs were down 10% year-over-year as revenue mix resulted in lower hardware costs, a more efficient implementation approach led to reduced travel spend and employee bonus expense decreased $700,000. The flat sequential cost coupled with the sequential increase in revenues resulted in margins improving from 56% to 61% which were the second highest since our acquisition of Healthland. And trailing only the fourth quarter of last year 63% margins which were heavily impacted by the aforementioned $12.3 million of high margin MU3 revenue, product development costs were down slightly from the third quarter of 2018 and flat year-over-year as the $400,000 year-over-year decrease in bonus expense has been offset by additional salary costs due to our strategic initiatives designed to improve provider adoption and clinical workflow and rejuvenate our post-acute offering. Sales and marketing costs increased $400,000 as improved implementation volumes drove commission expense higher while year-over-year costs decreased to $1.8 million due to $500,000 decrease in bonus expense, and a $1.3 million reduction in commission expense due to the aforementioned decline in MU3 revenues. General and administrative costs decreased $700,000 from the third quarter due to decreased costs related to severance and other employee benefits with increased health care costs mostly offset by decreased costs associated with our 401(k) match and pay time off benefits. Year-over-year costs are down $2.5 million primarily as health care costs and bad debt have normalized from the record high levels reached during the fourth quarter of 2017. For a bit of perspective, healthcare claims during the fourth quarter of 2017 were $400,000 higher than the second highest period since the Healthland acquisition. While bad debt expense was $1.1 million higher than the second highest period. Lastly, our effective tax rate during the quarter was 4%, primarily as an updated analysis of our state net operating loss carry-forwards resulted in improved estimates regarding future utilization, prompting a $1.1 million beneficial adjustment to the related valuation allowance. We've obviously seen a lot of noise in our effective tax rate over the past couple of years with the adoption of 2017's tax reform legislation and the ASC 730 Safe Harbor Directive related to our research and development tax credit. Assuming no other discrete items, we anticipate an effective tax rate of approximately 17% for 2019, with the ASC 730 Safe Harbor Directive impacting our expectations by 4.5% to 5%. One year ago, we pointed towards a healthy replacement market, significant long-term growth prospects for TruBridge, continued execution around our MU3 initiatives, and the strength of our recurring revenue base as the basis for our optimism and the future of CPSI. 2018's results have proven that optimism to be well-founded, and we remain excited for what the future holds at CPSI. For 2019, we're confident that continued execution around TruBridge and our cost savings initiative will result in continued revenue growth and improved profitability. And with that, we'd like to open the call up for any questions.